blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3587444

EP3587444 - MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.05.2025
Database last updated on 11.04.2026
FormerExamination is in progress
Status updated on  09.06.2020
FormerRequest for examination was made
Status updated on  20.03.2020
FormerThe application has been published
Status updated on  05.12.2019
Most recent event   Tooltip09.05.2025Application deemed to be withdrawnpublished on 11.06.2025  [2025/24]
Applicant(s)For all designated states
Delinia, Inc.
400 Technology Square, 10th Floor
Cambridge MA 02139 / US
[2020/01]
Inventor(s)01 / GREVE, Jeffrey
1066 Park Hills Road
Berkeley, CA 94708 / US
 [2020/01]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2020/01]
Application number, filing date19188596.120.07.2015
[2020/01]
Priority number, dateUS201461999241P21.07.2014         Original published format: US 201461999241 P
[2020/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3587444
Date:01.01.2020
Language:EN
[2020/01]
Search report(s)(Supplementary) European search report - dispatched on:EP04.10.2019
ClassificationIPC:C07K14/55, // A61K38/00, C07K16/00
[2020/01]
CPC:
C07K14/55 (EP,EA,GB,IL,KR,US); A61K38/00 (EP,IL,US); A61K38/1709 (IL,KR);
A61K38/2013 (GB,IL); A61P37/02 (EP,IL); A61P37/04 (EP,IL);
C07K16/00 (IL,US); C07K2319/30 (EP,GB,IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/17]
Former [2020/01]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:MOLEKÜLE ZUR SELEKTIVEN AKTIVIERUNG REGULATORISCHER T-ZELLEN ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN[2020/01]
English:MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES[2020/01]
French:MOLÉCULES D'ACTIVATION SÉLECTIVE DE LYMPHOCYTES T RÉGULATEURS POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES[2020/01]
Examination procedure12.03.2020Amendment by applicant (claims and/or description)
12.03.2020Examination requested  [2020/17]
12.03.2020Date on which the examining division has become responsible
15.06.2020Despatch of a communication from the examining division (Time limit: M06)
06.01.2021Reply to a communication from the examining division
08.06.2021Despatch of a communication from the examining division (Time limit: M06)
20.12.2021Reply to a communication from the examining division
20.01.2023Despatch of a communication from the examining division (Time limit: M04)
12.05.2023Reply to a communication from the examining division
01.02.2025Application deemed to be withdrawn, date of legal effect  [2025/24]
17.02.2025Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2025/24]
Parent application(s)   TooltipEP15824955.7  / EP3172227
Fees paidRenewal fee
26.07.2019Renewal fee patent year 03
26.07.2019Renewal fee patent year 04
26.07.2019Renewal fee patent year 05
14.07.2020Renewal fee patent year 06
15.07.2021Renewal fee patent year 07
15.06.2022Renewal fee patent year 08
14.06.2023Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.07.202410   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI] WO2012107417  (ROCHE GLYCART AG et al.)
 [A] WO2008003473  (MERCK PATENT GMBH et al.)
 [A] WO03048334  (EMD LEXIGEN RES CT CORP et al.)
 [T]   VAZQUEZ-LOMBARDI RODRIGO ET AL: "Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 8, 12 May 2017 (2017-05-12), XP002773463, ISSN: 2041-1723

DOI:   http://dx.doi.org/10.1038/ncomms15373
by applicantUS2004171154
 US2014286898
 US2007036752
 US7452966
 US6955807
   TANG, Q. ET AL., COLD SPRING HARB. PERSPECT. MED., vol. 3, 2013, pages 1 - 15
   MALEK, T. R. ET AL., IMMUNITY, vol. 33, 2010, pages 153 - 65
   SAADOUM, D. ET AL., N ENGL J MED., vol. 365, 2011, pages 2067 - 77
   KLATZMANN D, NAT REV IMMUNOL., vol. 15, 2015, pages 283 - 94
   SHANAFELT, A. B. ET AL., NAT BIOTECHNOL., vol. 18, no. 1, 2000, pages 1197 - 202
   CASSELL, D. J., CURR PHARM DES., vol. 8, 2002, pages 2171 - 83
   MARGOLIN, K., CLIN CANCER RES., vol. 13, 2007, pages 3312 - 9
   DAVEY, R. T., J INTERFERON CYTOKINE RES., vol. 28, 2008, pages 89 - 100
   CANTRELL, D. A., SCIENCE, vol. 224, 1984, pages 1312 - 1316
   KIRCHNER, G. L, BR J CLIN PHARMACOL., vol. 46, 1998, pages 5 - 10
   BELL ET AL., J AUTOIMMUN., vol. 56, 2015, pages 66 - 80
   SLEEP, D., BIOCHEM BIOPHYS ACTA, vol. 1830, 2013, pages 5526 - 34
   SCHLAPSCHY, M., PROTEIN ENG DES SET., vol. 20, 2007, pages 273 - 84
   SCHELLENBERGER, V., NAT BIOTECHNOI., vol. 27, 2009, pages 1186 - 90
   WANG, X. ET AL., SCIENCE, vol. 310, 2005, pages 1159 - 63
   PENICHET, M. L., HUM ANTIBODIES, vol. 8, 1997, pages 106 - 18
   SONDEL, P. M., ANTIBODIES, vol. 1, 2012, pages 149 - 71
   ZHENG, X. X. ET AL., J IMMUNOL., vol. 163, 1999, pages 4041 - 8
   ZHENG, X. X. ET AL., IMMUNITY, vol. 19, 2003, pages 503 - 14
   KARLINALTSCHUL, PROC. NATL. ACAD. SCL USA, vol. 87, 1990, pages 22264 - 2268
   KARLINALTSCHUL, PROC. NATL. ACAD. SCL USA, vol. 90, 1993, pages 5873 - 5877
   ALTSCHUL ET AL., J. MOL BIOL., vol. 215, 1990, pages 403 - 410
   ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
   CHEN ET AL., ADV DRUG DELIV REV., vol. 65, no. 10, 2013, pages 1357 - 69
   TAO, M. H. ET AL., J IMMUNOL., vol. 143, 1989, pages 2595 - 2601
   STORICI ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 773 - 776
   KREN ET AL., NAT. MED., vol. 4, 1998, pages 285 - 290
   CALISSANOMACINO, FUNGAL GENET, NEWSLETT., vol. 43, 1996, pages 15 - 16
   TIAN, NATURE, vol. 432, pages 1050 - 1054
   BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
   OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
   ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
   CZAJ.KOWS.KY ET AL., EMBO MOL MED., vol. 4, 2012, pages 1015 - 28
   SALFELD, J. G., NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 1369 - 72
   OGANESYAN ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR., vol. 64, 2008, pages 700 - 4
   DUMONT, J. A., BIODRUGS, vol. 20, 2006, pages 151 - 60
   LIU Z ET AL., J BIOL CHEM., vol. 20, no. 290, 2015, pages 7535 - 62
   ZHU Z ET AL., PROTEIN SCI., vol. 6, 1997, pages 781 - 8
   BELL ET AL., J AUTOIMMUN, vol. 56, 2015, pages 66 - 80
   HECHT ET AL., PLOS ONE, vol. 7, no. 1 1, 2012, pages e49345
   GILLIES ET AL., PROC NATL ACAD SCI, vol. 89, 1992, pages 1428 - 32
   ZHENG, X. X. ET AL., J IMMUNOL. 1999, vol. 163, 1999, pages 4041 - 8
   GILLIES S. D., CLIN CANCER RES., vol. 8, 2002, pages 210 - 6
   RIBAS A., J, TRANSL MED., vol. 7, 2009, pages 68
   KING D. M., J CLIN ONCOL., vol. 22, 2004, pages 4463 - 73
   ZHU E. F., CANCER CELL, vol. 27, no. 4, 2015, pages 489 - 501
   ARGOS CARGOS, J MOL BIOL., vol. 211, no. 4, 1990, pages 943 - 58
   MAHMUD, S. A. ET AL., JAKSTAT, vol. 2, 2013, pages e23154
   CHEN, Q. ET AL., J IMMUNOL, vol. 186, 2011, pages 6329 - 37
   REMINGTON: "The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO.
   ROSEMACKAY: "The Autoimmune Diseases", 2014, ACADEMIC PRESS
   SLEEP, D. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1830, 2013, pages 5526 - 34
   SCHELLENBERGER, V., NAT BIOTECHNOL., vol. 27, 2009, pages 1186 - 90
   SCHLAPSCHY, M., PROTEIN ENG DES SEL., vol. 20, 2007, pages 273 - 84
   MYSZKA, D. G. ET AL., PROTEIN SCI., vol. 5, 1996, pages 2468 - 78
   RING, A. M. ET AL., NAT IMMUNOL., vol. 13, 2012, pages 1187 - 95
   JAILWALA, P. ET AL., PLOS ONE, vol. 4, 2009, pages e6527
   LONG, S. A. ET AL., DIABETES, vol. 59, 2010, pages 407 - 15
   POLI, A ET AL., IMMUNOLOGY, vol. 126, no. 4, 2009, pages 458 - 65
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.